Archives
H3K18 Lactylation Drives NOD2-Mediated Pyroptosis in Astrocy
2026-04-18
H3K18 Lactylation-Mediated NOD2 Expression and Pyroptosis in Astrocytes: Mechanistic Insights from Bilirubin Encephalopathy Models
Study Background and Research Question
Bilirubin encephalopathy (BE), a severe neurological complication of neonatal hyperbilirubinemia, remains a significant global health issue, especially in low- and middle-income countries. Chronic forms such as kernicterus can result in irreversible neurological deficits, including neurodeafness and cerebral palsy (Li et al., 2025). While the toxic effects of unconjugated bilirubin (UCB) on neurons and glia are recognized, the upstream molecular regulators of glial cell death and neuroinflammation in BE are incompletely understood. In particular, the role of histone modifications—specifically lactylation—in modulating gene expression and inflammatory cell death (pyroptosis) in astrocytes had not been clarified prior to the present study.Key Innovation from the Reference Study
The central innovation of Li et al. (2025) is the identification of a glycolysis-dependent epigenetic mechanism—histone H3K18 lactylation (H3K18la)—that upregulates nucleotide-binding oligomerization domain 2 (NOD2) expression in astrocytes. This upregulation sensitizes astrocytes to pyroptosis in response to bilirubin exposure, linking metabolic shifts directly to inflammatory cell death via chromatin remodeling. The study demonstrates that H3K18la is not only increased upon UCB challenge in both primary astrocyte cultures and BE rat hippocampus, but also acts at the NOD2 promoter to drive transcription, bridging immunometabolic adaptation and neuroinflammatory signaling (Li et al., 2025).Methods and Experimental Design Insights
Li et al. employed a multi-layered experimental approach:- Primary rat astrocyte cultures and in vivo BE rat models were established to recapitulate UCB-induced neurotoxicity.
- Histone lactylation (specifically H3K18la) was quantified by immunoblotting and immunofluorescence in both systems.
- Glycolytic flux was perturbed pharmacologically to test causality between metabolism and epigenetic modification.
- Chromatin profiling (CUT&Tag) and transcriptomic analysis (RNA-seq) identified H3K18la enrichment at the NOD2 promoter and corresponding gene expression changes.
- Functional assays, including pyroptosis markers and signaling pathway readouts, established downstream effects on MAPK and NF-κB activation.
Core Findings and Why They Matter
The study reports several critical findings:- H3K18la upregulation in response to UCB: Astrocytes exposed to UCB showed significant increases in H3K18la both in vitro and in vivo, coinciding with elevated lactate levels and glycolytic activity (Li et al., 2025).
- Glycolysis inhibition attenuates H3K18la and pyroptosis: Blocking glycolytic flux reduced H3K18la, NOD2 expression, and markers of pyroptosis, supporting a direct link between metabolic state and gene regulation.
- H3K18la targets the NOD2 promoter: CUT&Tag revealed enrichment of H3K18la at the NOD2 promoter, and transcriptomic analysis confirmed increased NOD2 mRNA.
- NOD2 drives pro-pyroptotic signaling: Elevated NOD2 activated downstream MAPK and NF-κB pathways, exacerbating neuroinflammation and cell death.
Protocol Parameters
- assay | UCB exposure in primary astrocytes | 10–30 µM UCB for 24–48 h | models BE-relevant neurotoxicity | enables reproducible induction of pyroptosis | paper
- assay | Glycolysis inhibition (2-DG) | 5 mM 2-deoxyglucose | disrupts glycolytic flux in vitro | used to test metabolic-epigenetic coupling | paper
- assay | CUT&Tag for H3K18la | 1–2 µg antibody per 106 cells | maps histone modification at gene promoters | provides epigenetic landscape at NOD2 | paper
- assay | Caspase-1 activity and IL-1β release | ELISA/western blot | quantifies pyroptosis | measures cell death and inflammation | paper
- assay | Polyethylenimine Linear (PEI) transfection | 1–3 µg DNA per 106 cells; 2–6 µL PEI | optimal for transient gene expression in astrocytes | workflow_recommendation
Comparison with Existing Internal Articles
The reference study's focus on astrocyte epigenetics and pyroptosis adds a novel mechanistic layer to prior discussions in the APExBIO knowledgebase. For instance, the article "Polyethylenimine Linear (PEI, MW 40,000): Mechanistic Mastery in Neuroinflammation Models" (internal article) highlights how PEI-mediated DNA transfection enables researchers to manipulate gene expression in neuroinflammatory settings, such as BE models. Li et al. (2025) provide the first direct evidence that specific histone lactylation events can be targeted or mimicked in vitro, pointing to new experimental designs leveraging transient gene expression reagents. The workflow optimization guides—such as "Reliable Transfection with Polyethylenimine Linear (PEI), MW 40,000" (internal article)—are complementary, offering best practices for achieving high-efficiency transfection in astrocytes and related cell types. Together, these resources bridge molecular mechanism with actionable methodology.Limitations and Transferability
While the identification of the H3K18la/NOD2 axis in astrocyte pyroptosis is compelling, several limitations warrant consideration:- Species and model specificity: The findings are based on rat primary astrocytes and an in vivo rat model. Human astrocyte responses may differ, and translation to clinical BE requires validation.
- Temporal dynamics: The study examines acute responses; chronic adaptation of astrocytes to persistent hyperbilirubinemia remains to be characterized.
- Cell-type selectivity: While astrocytes are central here, microglia and neurons may exhibit distinct or overlapping regulatory circuits.
- Therapeutic targeting: The feasibility of directly modulating histone lactylation or NOD2 in vivo is currently theoretical; off-target effects and safety are unaddressed.